HomeComparePFE vs ICE

PFE vs ICE: Dividend Comparison 2026

PFE yields 6.20% · ICE yields 1.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ICE wins by $57.9K in total portfolio value
10 years
PFE
Pfizer Inc.
● Live price
6.20%
Share price
$27.76
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$51.1K
Annual income
$27,210.54
Full PFE calculator →
ICE
ICE
● Live price
1.25%
Share price
$156.94
Annual div
$1.96
5Y div CAGR
59.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$109.0K
Annual income
$44,156.55
Full ICE calculator →

Portfolio growth — PFE vs ICE

📍 ICE pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPFEICE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PFE + ICE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PFE pays
ICE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PFE
Annual income on $10K today (after 15% tax)
$526.66/yr
After 10yr DRIP, annual income (after tax)
$23,128.96/yr
ICE
Annual income on $10K today (after 15% tax)
$106.16/yr
After 10yr DRIP, annual income (after tax)
$37,533.07/yr
At 15% tax rate, ICE beats the other by $14,404.11/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PFE + ICE for your $10,000?

PFE: 50%ICE: 50%
100% ICE50/50100% PFE
Portfolio after 10yr
$80.0K
Annual income
$35,683.54/yr
Blended yield
44.58%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ICE right now

PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-0.9% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
ICE
Analyst Ratings
1
Strong
32
Buy
3
Hold
Consensus: Buy
Price Target
$192.86
+22.9% upside vs current
Range: $180.00 — $211.00
Altman Z
0.9
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PFE buys
0
ICE buys
0
No recent congressional trades found for PFE or ICE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPFEICE
Forward yield6.20%1.25%
Annual dividend / share$1.72$1.96
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR13.2%59.6%
Portfolio after 10y$51.1K$109.0K
Annual income after 10y$27,210.54$44,156.55
Total dividends collected$60.1K$83.1K
Payment frequencyquarterlyquarterly
SectorHealthcareFinancials
Analyst consensusHoldBuy
Analyst price target$27.50$192.86

Year-by-year: PFE vs ICE ($10,000, DRIP)

YearPFE PortfolioPFE Income/yrICE PortfolioICE Income/yrGap
1← crossover$9,161$701.38$10,899$199.32$1.7KICE
2$8,610$859.79$11,986$324.04$3.4KICE
3$8,366$1,081.25$13,357$531.54$5.0KICE
4$8,483$1,405.66$15,175$883.50$6.7KICE
5$9,084$1,907.24$17,735$1,497.24$8.7KICE
6$10,418$2,732.78$21,586$2,609.94$11.2KICE
7$13,007$4,193.56$27,836$4,738.36$14.8KICE
8$18,010$7,005.87$38,898$9,113.83$20.9KICE
9$28,216$12,979.89$60,617$18,996.59$32.4KICE
10$51,081$27,210.54$109,017$44,156.55$57.9KICE

PFE vs ICE: Complete Analysis 2026

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →

ICEFinancials

Intercontinental Exchange, Inc., together with its subsidiaries, operates regulated exchanges, clearing houses, and listings venues for commodity, financial, fixed income, and equity markets in the United States, the United Kingdom, the European Union, Singapore, Israel, and Canada. It operates through three segments: Exchanges, Fixed Income and Data Services, and Mortgage Technology. The company operates marketplaces for listing, trading, and clearing an array of derivatives contracts and financial securities, such as commodities, interest rates, foreign exchange, and equities, as well as corporate and exchange-traded funds; trading venues, including 13 regulated exchanges and 6 clearing houses; and offers futures and options products for energy, agricultural and metals, financial, cash equities and equity, over-the-counter, and other markets, as well as listings and data and connectivity services. It also provides fixed income data and analytic, fixed income execution, CDS clearing, and other multi-asset class data and network services. In addition, the company offers proprietary and comprehensive mortgage origination platform, which serves residential mortgage loans; closing solutions that provides customers connectivity to the mortgage supply chain and facilitates the secure exchange of information; data and analytics services; and Data as a Service for lenders to access data and origination information. Intercontinental Exchange, Inc. was founded in 2000 and is headquartered in Atlanta, Georgia.

Full ICE Calculator →
📬

Get this PFE vs ICE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PFE vs JNJPFE vs MRKPFE vs ABBVPFE vs BMYPFE vs LLYPFE vs SCHDPFE vs JEPIPFE vs O

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.